MedPath

Chinese Psoriasis Real World Evidence Research

Recruiting
Conditions
Psoriasis
Interventions
Other: NIS
Registration Number
NCT04465838
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Brief Summary

This research is a multicenter,observational study under real world settings in patients diagnosed as psoriasis by dermatologist in the clinic. As patient's choice of medication should be fully respected, all the patients can choose the treatments they prefer, like phototherapy, traditional systemic therapy or biologics. And the study was conducted to compare the effectiveness among different choices of medication in Chinese psoriasis patients.

Detailed Description

Psoriasis is a chronic, recurrent inflammatory disease which is caused by heredity, environment and other factors. The typical clinical manifestation are erythematosquamous lesions, and the disease can progress to involve several organs. In view of its complex pathogenesis, there exists various of treatment of psoriasis like traditional systemic drugs and biologics.

This study is an observational, multi-centre study based on real-world evidence. Inclusion criteria is the patients who visit the clinic diagnosed psoriasis by the dermatologist. There existed no exclusion criteria. Information were most collected by a phone application called "Psoriasis New World".

Primary outcome measure is the percentage of patients who achieved a PASI reduction of 100% (PASI 100). And Psoriasis Area and Severity Index includes scores of erythema, infiltration and desquamation, weighted by area of involvement in each regions (head and neck, upper extremities, trunk, lower extremities), with higher PASI scores indicating worse condition. Also, static Physician Global Assessment (sPGA), static Investigator Global Assessment (sIGA), Body surface area (BSA) and Dermatology Life Quality Index (DLQI) are measured to assess the severity of psoriasis and the change of the disease condition. It is important to monitor all the Adverse Events (AEs) over the whole study. In addition, the laboratory examinations of patients such as liver function are also collected.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
10000
Inclusion Criteria
  • all the patients diagnosed as psoriasis by dermatologist in clinic.
Exclusion Criteria
  • None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
PsoriasisNISThis is a non-interventional study (NIS). All the patients diagnosed as psoriasis by the dermatologists in the clinic are included in this study no matter what kind of treatment they adopt.
Primary Outcome Measures
NameTimeMethod
The percentage of patients who achieved a PASI reduction of 100% (PASI 100)6 months

Psoriasis Area and Severity Index includes scores of erythema, infiltration and desquamation, weighted by area of involvement in each regions (head and neck, upper extremities, trunk, lower extremities), with higher PASI scores indicating worse condition. The percentage of patients who achieved a PASI reduction of 100% (PASI 100) will be measured.

Secondary Outcome Measures
NameTimeMethod
The percentage of patients who achieved a PASI reduction of 75% (PASI 75)6 months and 12 months

PASI75 response is the percentage of participants who achieved at least a 75% reduction from baseline in PASI score.

The percentage of patients who achieved a PASI reduction of 100% (PASI 100)6 months and 12 months

PASI100 represents complete clearance.

static Physician Global Assessment (sPGA) = 06 months and 12 months

static Physician Global Assessment (sPGA) is an assessment of severity of psoriasis on 5-point scale ranging from 0 to 4.

Adverse Events (AEs)Up to 12 months

Number of patients with adverse events

Visual Analog Scale (VAS)6 months and 12 months

Visual Analog Scale (VAS) is used to measure lesion pruritus from 0 to 10. The higher score is, the greater discomfortableness participant has.

The percentage of patients who achieved a PASI reduction of 50% (PASI 50)6 months and 12 months

PASI50 response is the percentage of participants who achieved at least a 50% reduction from baseline in PASI score.

Dermatology Life Quality Index (DLQI) =06 months and 12 months

The Dermatology Life Quality Index (DLQI) is a questionnaire used to measure the impact of a skin disease.

static Investigator Global Assessment (sIGA) = 06 months and 12 months

static Investigator Global Assessment (sIGA) is an assessment of severity of psoriasis on 5-point scale ranging from 0 to 4.

Body surface area (BSA)6 months and 12 months

The percentage of BSA represents the area of involvement, which can be estimated by the entire palm of the patient.

Trial Locations

Locations (29)

Second Affiliated Hospital, School of Medicine, Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

The Fifth People's Hospital of Hainan Province

🇨🇳

Hainan, China

the First Hospital of Hebei Medical University

🇨🇳

Hebei, China

the Second Affiliated Hospital of Harbin Medical Unviersity

🇨🇳

Heilongjiang, China

Henan Provincial Peoples' Hospital

🇨🇳

Henan, China

the Affiliated Hospital of Inner Mongolia Medical University

🇨🇳

Hohhot, China

Yanbian University Hospital

🇨🇳

Jilin, China

Shanghai Dermatology Hospital

🇨🇳

Shanghai, China

the Second Affiliated Hospital of Xi'an Jiaotong University

🇨🇳

Shanxi, China

the First hospital of China Medical University

🇨🇳

Shenyang, China

First Affiliated Hospital, School of Medicine, Shihezi University

🇨🇳

Xinjiang, China

the Second Affiliated Hospital of Kunming Medical University

🇨🇳

Yunnan, China

The Peoples' Hospital of Guangxi Zhuang Autonomous Region

🇨🇳

Guangxi, China

the Affiliated Hospital of Guizhou Medical University

🇨🇳

Guizhou, China

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

🇨🇳

Hubei, China

the First Affiliated Hospital of Fujian Medical University

🇨🇳

Fujian, China

Xining First Hospital

🇨🇳

Qinghai, China

Taiyuan Central Hospital

🇨🇳

Shanxi, China

Shandong Provincial Hospital for Skin Diseases

🇨🇳

Shandong, China

Sichuan Provincial People's Hospital

🇨🇳

Sichuan, China

Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

🇨🇳

Tianjin, China

General Hospital of Ningxia Medical University

🇨🇳

Yinchuan, China

Beijing Children's Hospital Affiliated to Capital Medical University

🇨🇳

Beijing, China

the First Affiliated Hospital of Chongqing Medical University

🇨🇳

Chongqing, China

General Hospital of Lanzhou Military Region

🇨🇳

Gansu, China

Sun Yat-sen Memorial Hospital

🇨🇳

Guangdong, China

Xiangya Hospital, Central South University

🇨🇳

Hunan, China

the Second Affiliated Hospital of Nanchang University

🇨🇳

Jiangxi, China

Institute of Dermatology, Chinese Academy of Medical Sciences

🇨🇳

Nanjing, China

© Copyright 2025. All Rights Reserved by MedPath